Angiogenesis in normal and neoplastic ovaries.
Ovarian physiology is intricately connected to hormonally regulated angiogenic response. Recent advances in the post genomic revolution have significantly impacted our understanding of ovarian function. In an angiogenesis perspective, the ovary offers a unique opportunity to unravel the molecular orchestration of blood vessel development and regression under normal conditions. A majority of ovarian cancers develop from the single layer of epithelium surrounding the ovaries. Angiogenesis is critical for the development of ovarian cancer and its peritoneal dissemination. The present review summarizes recent findings on the angiogenic response in neoplastic ovaries and discusses the prospects of using anti-angiogenic approaches to treat ovarian cancer.
Ramakrishnan
S
S
Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA. sunda001@umn.edu
Subramanian
I V
IV
Yokoyama
Y
Y
Geller
M
M
D043925:Angiogenesis Inducing Agents / Q000378:metabolism; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D009389:Neovascularization, Pathologic / Q000503:physiopathology*; D018919:Neovascularization, Physiologic / Q000502:physiology*; D010051:Ovarian Neoplasms / Q000503:physiopathology* / Q000628:therapy; D010053:Ovary / Q000098:blood supply*; D011487:Protein Conformation
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors